MARKET

AGTC

AGTC

AGTC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.990
-0.050
-1.24%
After Hours: 3.950 -0.04 -1.00% 19:59 04/16 EDT
OPEN
3.900
PREV CLOSE
4.040
HIGH
4.000
LOW
3.660
VOLUME
2.51M
TURNOVER
--
52 WEEK HIGH
9.67
52 WEEK LOW
3.560
MARKET CAP
170.20M
P/E (TTM)
-1.7663
1D
5D
1M
3M
1Y
5Y
Applied Genetic and TeamedOn ink licensing deal for gene therapy development
Applied Genetic Technologies ([[AGTC]] -0.6%) and gene therapy company TeamedOn International have signed a licensing agreement to advance gene therapy to treat X-linked retinoschisis ((XLRS)), an inherited disease that causes
Seekingalpha · 4d ago
H.C. Wainwright Sticks to Their Buy Rating for Applied Genetic Technologies (AGTC)
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Applied Genetic Technologies (AGTC), with a price target of
SmarterAnalyst · 4d ago
BRIEF-TeamedOn, AGTC Report a Licensing Agreement Advancing X-Linked Retinoschisis Gene Therapy Program
reuters.com · 4d ago
TeamedOn and AGTC Announce a Licensing Agreement Advancing X-Linked Retinoschisis Gene Therapy Program
TeamedOn International, Inc., a biotechnology company dedicated to advancing gene therapies for rare diseases, including ophthalmic indications, and Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology
Benzinga · 4d ago
BRIEF-Applied Genetic Technologies Corp Files For Mixed Shelf Of Upto $250 Million
reuters.com · 04/02 22:25
AGTC to Participate in Upcoming Virtual Biotech Corporate Access Day and Cell and Gene Conference
GAINESVILLE, Fla. and CAMBRIDGE, Mar 31, 2021 (GLOBE NEWSWIRE via COMTEX) -- GAINESVILLE, Fla. and CAMBRIDGE, Mass., March 31, 2021 (GLOBE NEWSWIRE) --...
GlobeNewswire · 03/31 12:00
H.C. Wainwright Sticks to Its Buy Rating for Applied Genetic Technologies (AGTC)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Applied Genetic Technologies (AGTC) today and set a price target of $24.00. The
SmarterAnalyst · 03/31 10:26
AGTC Announces New Initiatives To Enhance The Patient Journey In Its XLRP Trials
-AGTC's deep commitment to the patient voice drives solutions to support patient access to information and to improve the experience of patients participating in clinical trials-
GlobeNewswire · 03/25 11:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AGTC. Analyze the recent business situations of AGTC through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AGTC stock price target is 16.00 with a high estimate of 35.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 99
Institutional Holdings: 15.11M
% Owned: 35.43%
Shares Outstanding: 42.66M
TypeInstitutionsShares
Increased
23
670.20K
New
6
127.82K
Decreased
20
1.00M
Sold Out
11
1.12M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.60%
Pharmaceuticals & Medical Research
+0.89%
Key Executives
Chairman/Independent Director
Scott Koenig
President/Chief Executive Officer/Director
Susan Washer
Chief Financial Officer
William Sullivan
Executive Vice President
Matthew Feinsod
Chief Scientific Officer
Mark Shearman
Vice President
Stephen Potter
Independent Director
William Aliski
Independent Director
Edward Hurwitz
Independent Director
Ivana Magovcevic-Liebisch
Independent Director
James Rosen
Independent Director
Anne VanLent
Director
Ivana Magovcevic
No Data
  • All
  • Financials
  • Insiders
More
About AGTC
Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company uses gene therapy platform to develop genetic therapies for patients suffering from rare and debilitating diseases. Its focus is in the field of ophthalmology where it has active clinical programs in X-linked retinitis pigmentosa (XLRP), achromatopsia (ACHM), and optogenetics. The Company has approximately one preclinical program in otology and three preclinical programs targeting central nervous system disorders (CN), including adrenoleukodystrophy (ALD), frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company's optogenetics program is being developed in collaboration with Bionic Sight, LLC and its otology program is being developed in collaboration with Otonomy, Inc. In addition to its product pipeline, the Company has also developed broad technological and manufacturing capabilities in synthetic promoter development and optimization.

Webull offers kinds of Applied Genetic Technologies Corp stock information, including NASDAQ:AGTC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGTC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AGTC stock methods without spending real money on the virtual paper trading platform.